If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

This can lead to inflammation and an increased risk of eosinophilic asthma. If you have severe asthma or your asthma symptoms do not improve with standard treatments, your healthcare provider may ...

Current treatments focus on eosinophilic asthma, neglecting non-eosinophilic types. Developments in biologic therapies for severe asthma, challenges remain in managing T-helper cell type 2 (T2)-low ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

A common scenario is the patient with EoE who develops heartburn when on well-established EoE nutritional or steroid treatment ... alterations associated with eosinophilic inflammation.

Intermediate group 2 innate lymphoid cells (ILC2s) appear to be able to get around cutting-edge asthma treatments by ...

Asthma & Allergy Foundation of America ... Allergy-test-based elimination diets for the treatment of eosinophilic esophagitis: A systematic review of their efficacy. J Clin Med.

Previously approved in China for severe eosinophilic asthma in adult and adolescent individuals of ... "China’s NMPA approves GSK’s Nucala for CRSwNP treatment" was originally created and published by ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

While treatment of EoE is complicated by a number ... 1 720 777 7457 Fax: +1 720 777 7277 [email protected]. Eosinophilic esophagitis (EoE) presents with a constellation of symptoms ...